Cedarleaf Therapeutics Begins Phase 2 Trial for Chronic Pain Treatment

Cedarleaf Therapeutics has dosed the first patients in a Phase 2 clinical trial of CL-207, an investigational non-opioid treatment for chronic musculoskeletal pain. The randomized study will enroll roughly 240 patients across 18 sites.

The company expects topline results in the second half of next year.